Quince Therapeutics Inc QNCX

Morningstar Rating
$31.73 +2.37 (8.07%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

QNCX is trading at a LOCK|jL<^! premium.
Price
$31.99
Fair Value
LOCK|.qbj&#<
Uncertainty
LOCK|tn LH<#
1-Star Price
LOCK|.f<zdmWc
5-Star Price
LOCK|.?^%>%F
Economic Moat
LOCK|qcCX
Capital Allocation
—

Trading Information

Previous Close Price
$29.36
Day Range
$29.84–37.00
52-Week Range
$15.10–909.98
Bid/Ask
$31.70 / $34.00
Shares Outstanding
1.02M
Market Cap
$32.27M
Volume/Avg
138,744 / 30,254

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
38

Valuation

Metric
QNCX
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
QNCX
Quick Ratio
14.23
Current Ratio
14.52
Interest Coverage
—
Quick Ratio
QNCX

Profitability

Metric
QNCX
Return on Assets (Normalized)
−32.22%
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
−1,340.89%
Return on Assets
QNCX

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|hyVc^nLOCK|>!j%$129B
Moderna Inc
MRNA
LOCK|R^S?j>LOCK|%M$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|s^<$!gLOCK|<s!&Z$77B
argenx SE ADR
ARGX
LOCK|q&p#qtLOCK|mH#$51B
BeOne Medicines Ltd ADR
ONC
LOCK|&>sfttKLOCK|DF$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|y%l$%%RLOCK|d!bQ$31B
Royalty Pharma PLC Class A
RPRX
LOCK|BHm&Xw^LOCK|&pt&$25B
BioNTech SE ADR
BNTX
LOCK|f%>%<$LOCK|LCP$24B
Incyte Corp
INCY
LOCK|d#rsB>LOCK|$V$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|<?L?QVZLOCK|^&V$14B

Sponsor Center